PINK
DNPUF

Sumitomo Dainippon Pharma Co. Ltd

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Sumitomo Dainippon Pharma Co. Ltd Stock Price

Vitals

Today's Low:
$3.718
Today's High:
$3.718
Open Price:
$3.718
52W Low:
$5.15
52W High:
$8.0848
Prev. Close:
$4.37
Volume:
275

Company Statistics

Market Cap.:
$2.06 billion
Book Value:
1023.804
Revenue TTM:
$555.54 billion
Operating Margin TTM:
-6.87%
Gross Profit TTM:
$402.91 billion
Profit Margin:
-13.41%
Return on Assets TTM:
-1.95%
Return on Equity TTM:
-17.9%

Company Profile

Sumitomo Dainippon Pharma Co. Ltd had its IPO on under the ticker symbol DNPUF.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Sumitomo Dainippon Pharma Co. Ltd has a staff strength of 0 employees.

Stock update

Shares of Sumitomo Dainippon Pharma Co. Ltd opened at $3.72 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.72 - $3.72, and closed at $3.72.

This is a -14.92% slip from the previous day's closing price.

A total volume of 275 shares were traded at the close of the day’s session.

In the last one week, shares of Sumitomo Dainippon Pharma Co. Ltd have slipped by -36.93%.

Sumitomo Dainippon Pharma Co. Ltd's Key Ratios

Sumitomo Dainippon Pharma Co. Ltd has a market cap of $2.06 billion, indicating a price to book ratio of 0.6426 and a price to sales ratio of 0.0053.

In the last 12-months Sumitomo Dainippon Pharma Co. Ltd’s revenue was $555.54 billion with a gross profit of $402.91 billion and an EBITDA of $3.08 billion. The EBITDA ratio measures Sumitomo Dainippon Pharma Co. Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Sumitomo Dainippon Pharma Co. Ltd’s operating margin was -6.87% while its return on assets stood at -1.95% with a return of equity of -17.9%.

In Q4, Sumitomo Dainippon Pharma Co. Ltd’s quarterly earnings growth was a positive 547.8% while revenue growth was a negative 25.5%.

Sumitomo Dainippon Pharma Co. Ltd’s PE and PEG Ratio

Forward PE
19.4553
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-0.15 per share while it has a forward price to earnings multiple of 19.4553 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sumitomo Dainippon Pharma Co. Ltd’s profitability.

Sumitomo Dainippon Pharma Co. Ltd stock is trading at a EV to sales ratio of 0.0049 and a EV to EBITDA ratio of 0.0283. Its price to sales ratio in the trailing 12-months stood at 0.0053.

Sumitomo Dainippon Pharma Co. Ltd stock pays annual dividends of $21 per share, indicating a yield of 2.03% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$1,371.52 billion
Total Liabilities
$309.55 billion
Operating Cash Flow
$0
Capital Expenditure
$3.92 billion
Dividend Payout Ratio
0%

Sumitomo Dainippon Pharma Co. Ltd ended 2024 with $1,371.52 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1,371.52 billion while shareholder equity stood at $635.15 billion.

Sumitomo Dainippon Pharma Co. Ltd ended 2024 with $0 in deferred long-term liabilities, $309.55 billion in other current liabilities, in common stock, $486.20 billion in retained earnings and $211.57 billion in goodwill. Its cash balance stood at $265.77 billion and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $244.09 billion.

Sumitomo Dainippon Pharma Co. Ltd’s total current assets stands at $578.52 billion while long-term investments were $0 and short-term investments were $22.49 billion. Its net receivables were $149.39 billion compared to accounts payable of $52.67 billion and inventory worth $90.47 billion.

In 2024, Sumitomo Dainippon Pharma Co. Ltd's operating cash flow was $0 while its capital expenditure stood at $3.92 billion.

Comparatively, Sumitomo Dainippon Pharma Co. Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$3.72
52-Week High
$8.0848
52-Week Low
$5.15
Analyst Target Price
$

Sumitomo Dainippon Pharma Co. Ltd stock is currently trading at $3.72 per share. It touched a 52-week high of $8.0848 and a 52-week low of $8.0848. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $7.89 and 200-day moving average was $10.44 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 5859.7% of the company’s stock are held by insiders while 1994.1% are held by institutions.

Frequently Asked Questions About Sumitomo Dainippon Pharma Co. Ltd

The stock symbol (also called stock or share ticker) of Sumitomo Dainippon Pharma Co. Ltd is DNPUF

The IPO of Sumitomo Dainippon Pharma Co. Ltd took place on

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
$12.46
-0.08
-0.64%
$5637.4
-288.2
-4.86%
CONX Corp (CONXW)
$0.15
-0
-2.53%
$142.85
-9.6
-6.3%
$1.27
-0.05
-3.79%
$787.3
-40.85
-4.93%
$23.2
-0.08
-0.34%
$48.06
0.37
+0.78%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson’s disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Address

6-8, Doshomachi 2-chome, Osaka, Japan, 541-0045